Comparative survival associated with use of targeted vs nontargeted therapy in medicare patients with metastatic renal cell carcinoma

P Li, J Jahnke, AR Pettit, YN Wong… - JAMA Network …, 2019 - jamanetwork.com
Importance Targeted therapies for advanced renal cell carcinoma (RCC) have shown
increased tolerability and survival advantages over older treatments in clinical trials, but …
被引用次数：16 相关文章

Comparative Survival Associated With Use of Targeted vs Nontargeted Therapy in Medicare Patients With Metastatic Renal Cell Carcinoma.

P Li, J Jahnke, AR Pettit, YN Wong… - JAMA Network …, 2019 - search.ebscohost.com
Abstract Key Points: Question: Is the use of targeted therapy associated with survival
advantages compared with older treatments in a real-world population of patients with …
[HTML] nih.gov

[HTML][HTML] Comparative Survival Associated With Use of Targeted vs Nontargeted Therapy in Medicare Patients With Metastatic Renal Cell Carcinoma

P Li, J Jahnke, AR Pettit, YN Wong… - JAMA Network Open, 2019 - ncbi.nlm.nih.gov
Comparative Survival Associated With Use of Targeted vs Nontargeted Therapy in Medicare
Patients With Metastatic Renal Cell Carcinoma - PMC Back to Top Skip to main content NIH …

Comparative Survival Associated With Use of Targeted vs Nontargeted Therapy in Medicare Patients With Metastatic Renal Cell Carcinoma

P Li, J Jahnke, AR Pettit, YN Wong… - JAMA network …, 2019 - pubmed.ncbi.nlm.nih.gov
Importance Targeted therapies for advanced renal cell carcinoma (RCC) have shown
increased tolerability and survival advantages over older treatments in clinical trials, but …

Comparative Survival Associated With Use of Targeted vs Nontargeted Therapy in Medicare Patients With Metastatic Renal Cell Carcinoma.

P Li, J Jahnke, AR Pettit, YN Wong, JA Doshi - JAMA Network Open, 2019 - europepmc.org
Comparative Survival Associated With Use of Targeted vs Nontargeted Therapy in Medicare
Patients With Metastatic Renal Cell Carcinoma. - Abstract - Europe PMC Sign in | Create an …

Comparative Survival Associated With Use of Targeted vs Nontargeted Therapy in Medicare Patients With Metastatic Renal Cell Carcinoma.

P Li, J Jahnke, AR Pettit, YN Wong, JA Doshi - JAMA Network Open, 2019 - europepmc.org
Comparative Survival Associated With Use of Targeted vs Nontargeted Therapy in Medicare
Patients With Metastatic Renal Cell Carcinoma. - Abstract - Europe PMC Sign in | Create an …